Skip to main content
main-content

30.06.2018 | Gynecologic Oncology | Ausgabe 2/2018

Archives of Gynecology and Obstetrics 2/2018

Levothyroxine use and the risk of breast cancer: a nation-wide population-based case–control study

Zeitschrift:
Archives of Gynecology and Obstetrics > Ausgabe 2/2018
Autoren:
Chieh-Chen Wu, Ya-Yu Yu, Hsuan-Chia Yang, Phung Anh Nguyen, Tahmina Nasrin Poly, Md. Mohaimenul Islam, Usman Iqbal, Hafash Arshed Ali Khan, Yao-Chin Wang, Yung-Tzu Cheng, Yu-Chuan Li, Wen-Shan Jian
Wichtige Hinweise
Yu-Chuan Li and Wen-Shan Jian have contributed equally to this work.

Abstract

Purpose

To investigate whether the use of levothyroxine was associated with breast cancer risk.

Methods

We conducted a population-based case–control study in Taiwan. Cases consisted of all patients who were aged 20 years and older, and had a first-time diagnosis of breast cancer for the period between 2001 and 2011. The controls were matched to the cases by age, sex, year, and month of diagnosis. Adjusted odd ratios (ORs) and 95% confidence intervals (CIs) were estimated by a conditional logistic regression.

Results

We examined 65,491 breast cancer cases and 261,964 controls. We found that use of levothyroxine was associated with a significant increase in breast cancer risk (OR 1.24, 95% CI 1.15–1.33; P < 0.001). Compared with no use levothyroxine, the adjusted odd ratio was 1.22 (95% CI 1.11–1.35; P = 0.01) for the group having been prescribed levothyroxine 2 months to 1 year, and 1.26 (95% CI 1.12–1.41; P < 0.01) for the group with more than 1 year. When stratified by age, the adjusted odd ratio was 1.45 (95% CI 1.23–1.71; P < 0.01) for the patients aged 65 years or more and 1.19 (95% CI 1.09–1.29, P < 0.01) for the patients aged less than 65 years.

Conclusion

The results of the present study are the first to suggest that levothyroxine use increased the risk of breast cancer. However, a larger long-term prospective randomized-controlled trial specifically designed to assess the effect of levothyroxine use on the risk of developing breast cancer is needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

Archives of Gynecology and Obstetrics 2/2018 Zur Ausgabe

Gynecologic Endocrinology and Reproductive Medicine

High-density lipoproteins (HDL) composition and function in preeclampsia

  1. Sie können e.Med Gynäkologie & Urologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Gynäkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise